Research Reports

Market Overview

• The Global Oncology Therapy Market is expected to grow at a high CAGR during the forecast period (2019-2026)
• Cancer therapies are the drugs which are designed to inhibit the growth and proliferation of cancer, by interfering with specific molecules, such as proteins or DNA, which are involved in the growth and expansion of cancerous cells. Various types of cancers such as lung cancer, colorectal, breast cancer, kidney cancer and others are predominant among the population. Treatment of cancer mainly depends upon the stages of the disease progression. Chemotherapy is mainly used in the earlier stages whereas other therapy options such as targeted therapy, immunological therapy and radiation therapy are used in late stage. However, the Targeted therapy is expected to dominate the market. This is mainly used due to its fewer side effects offered by the treatment compared to the conventional therapy and cost-effective nature and the increased number of Targeted therapy drugs.

Download free sample: https://www.datamintelligence.com/download-sample/oncology-therapy-market

Market Dynamics

• The major driving forces are rise in incidences of cancer, which has led to increased demand for cancer drugs, increased demand for precision medicine, increased number of collaborations between the pharmaceutical companies, increase in number of recent advances in technology, increasing research activities in cancer, increasing geriatric population globally. In addition, the rise in healthcare expenditure worldwide and rise in number of promising pipeline products are expected to boost the market expansion.
• Rising incidences of cancer is one of the dominating factors, propelling the global oncology therapy market. For instance, According to WHO, cancer is the second leading cause of death worldwide, and is responsible for 9.6 million deaths in 2018 and globally, about 1 in 6 deaths is only because of cancer. Approximately 70% of deaths from cancer occur in low and middle-income countries. Also, in 2018, 2.09 million lung cancer and 2.09 million breast cancer cases were registered globally. The International Agency for Research on Cancer has reported that there will be 413,000 new cases in the forecast period. Cancer causing infections, such as hepatitis and human papilloma virus (HPV), are responsible for up to 25% of cancer cases in low- and middle-income countries. According to the American Institute for Cancer Research in 2018, age-standardized rate for all cancers (including non-melanoma skin cancer) for men and women combined was 197.9 per 100,000. The rate was higher for men (218.6 per 100,000) than women (182.6 per 100,000). The highest cancer rate for men and women together was in Australia, with 468.0 people per 100,000.
• Increased demand for precision medicine due to rising incidence of cancer, to treat various types of cancer globally is expected to boost the oncology therapy market. Rise in number of FDA approvals of precision medicine in oncology and government initiatives are some of the factors driving the market. For instance, in 2014, the United Kingdom has launched the 100K Genomes Project with the objective of sequencing 100,000 genomes of patients in the National Health Service (NHS) in the search for biomarkers for cancer and rare genetic diseases. The Precision Medicine Initiative® (PMI) is a $215 million investment in the National Institutes of Health’s (NIH) fiscal year 2016 budget to accelerate the biomedical research that can lead to individualized approach. The NCI is using $70 million of that investment to advance the field of precision oncology.
• Increasing number of collaborations between the pharmaceutical companies is expected to boost the market over the period of forecast. For instance, recent collaborations in the precision oncology research is driving the share of the segment leading to improved health care. For instance, On April 12, 2019 Pfizer is currently working with Boston-based Concerto Health AI for a collaboration that will use Concerto's Eureka Health artificial intelligence technology to precision oncology research. On October 17, 2018 Novartis had a strategic collaboration with Foundation medicine, allowing the development of companion diagnostic (CDx) tests for the Novartis portfolio of targeted immuno-oncology and oncology therapeutics. In 2018, GE Healthcare collaborated with Roche that helped them to develop digital integrated platform for critical care treatment and oncology
• Increase in number of recent advances in technology and the use of information is expected to drive the market over the period for forecast. This is owing to the advances in drugs and medical devices, as well as the use of big data, artificial intelligence and mobile apps to drive better patient engagement. Big data has made the treatments become easier as it provides patient navigation, patient-reported outcomes, and identification of high-risk patients, patient satisfaction scoring, and giving them appropriate treatment. AI uses DL algorithms and Convolutional Neural Network (CNN) which analyzes pixel-level information from images in oncology. For instance, the advancement in technology is the increasing use of mobile apps across many countries which can improve diagnosis, treatment, adherence and other aspects of patient experience in cancer. Also, Pay-for-Performance with CAR-T Therapy, in 2018, a new treatment was approved by the Genentech which is called Chimeric Antigen Receptor T- cell (CAR-T) therapy. The therapy is comparatively expensive for the patients but to make it affordable for them, an innovative pay-for-performance contract was also announced in conjunction with the launch of first CAR-T therapy. The new radio labeled drug sustainability has lowered the risk and the death rate of cancer patients. The medicine is composed of radioisotope LU attached to octreotide that binds the tumor cells that enable the radiations and directly target the cancer cells. Thus, the recent advancements in the technology are expecting to the boost the market.
• However, onset of adverse effects associated with the use of cancer drugs and high costs related with the cancer drug development are among a few major factors expected to hamper the growth of the oncology therapy market.

Market Segmentation Analysis

• The global Oncology therapy market can be segmented by treatment type as targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others. By type the market is segmented as breast cancer, lung cancer, blood cancer, kidney cancer, hematologic cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, and other cancer types. By end-users, the   market is segmented as hospitals, specialty clinics, cancer and radiation therapy centers.
• By therapy, targeted therapy is expected to grow at a high rate over the period of forecast. The target therapy includes hormone therapies, apoptosis inducers, gene expression modulators, angiogenesis inhibitors, PARP inhibitors, signal transduction inhibitors, and toxin delivery molecules. These drugs inhibit the growth and spread of cancer cells and limit harm to the normal cells. This is owing to the increased number of US FDA approvals of certain monoclonal antibodies in the recent years like Seattle genetics’s Brentuximab vedotin (Adcetris) in 2018, Rituximab (Rituxan) and checkpoint inhibitors like Merck’s pembrolizumab (Keytruda) in 2018 for the Hodgkin lymphoma treatment. Lenvatinib (Lenvima) which is a platelet derived growth factor alpha receptor antagonist in August 16, 2018 of Eisai Co Ltd and sunitinib which is a tyrosine kinase inhibitor in November 16, 2017 of Pfizer are the drugs used to treat renal cell carcinoma. Trastuzumab (Herceptin) is a monoclonal antibody often used along with chemotherapy for the treatment of breast cancer.
• Immunotherapy is expected to grow at the highest CAGR over the period of forecast. Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. Immunotherapy drugs may be used as a first-line treatment for melanoma and some other cancers, or they may be used in combination with other treatments, such as chemotherapy and surgery. The U.S. Food and Drug Administration (FDA) has approved certain checkpoint inhibitor drugs, which work by targeting signaling proteins that allow cancer cells to hide from the immune system, to treat some cases of advanced or metastatic melanoma. Medications used in immunotherapy are ipilimumab, nivolumab, pembrolizumab, talimogene, and laherparepvec. Also, certain immunomodulators like Nivolumab (Opdivo) and Avelumab (Bavencio) are used in the treatment of renal cell carcinoma.
• By type, breast cancer is expected to grow at a high rate over the period of forecast. This is owing to the increase in prevalence of breast cancer cases across the globe, rise in the number of targeted therapies, the increasing awareness of breast cancer among the disease population and increase in survival rate of breast cancer population. For instance, according to the American Cancer Society in 2018, it is estimated that 266,120 new cases of invasive breast cancer are diagnosed in women in the US. Breast Cancer organization in 2018, reported that about 1 in 8 U.S. women (about 12%) developed invasive breast cancer over the course of her lifetime. Targeted therapy is mainly used due to its fewer side effects offered by the treatment compared to the conventional therapy and cost-effective nature. Targeted therapies like trastuzumab (Herceptin), Pertuzumab (Perjeta), Afinitor (mTOR inhibitor), Lynparza (PARP inhibitor) are used in the treatment of breast cancer.
• Lung cancer is expected to grow at the highest CAGR over the period of forecast. This is owing to the rise in incidences of lung cancer, increased number of targeted therapies and increased demand for precision medicine. According to the World Health Organization in 2018, 2.09 million lung cancer cases are estimated. The American Institute of Cancer Research has reported that the Lung cancer is the most commonly occurring cancer in men and the third most commonly occurring cancer in women. There were 2 million new cases in 2018. Targeted drugs which are angiogenesis inhibitors like Bevacizumab (Avastin) and Ramucirumab (Cyramza) are used in the treatment of lung cancer. On January 18, 2018, QIAGEN N.V. announced that the US FDA has approved a PMA supplement for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the usage of Boehringer Ingelheim's targeted therapy GILOTRIF® (afatinib) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant epidermal growth factor receptor (EGFR) mutations. On February 27, 2019, Thermo Fischer has received expanded approval in Japan for its Oncomine Dx Target Test to be used in non-small cell lung cancer.  

Market Competitive Trend Analysis

• The market is moderately concentrated with a limited number of Key players operating in the global oncology therapy market. Pfizer, Novartis, Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson and others are some of the vendors in the market.
• The global oncology therapy market is expected to witness substantial growth during the forecast period. This can be attributed to the great investments by market players in the research and development of oncology therapy and the diversified product portfolio which are responsible for strengthening the position of these companies in the market. Also, they have been adopting key strategies, such as new product developments, acquisitions, and expansions, to increase their share in the cold chain packaging market. For instance, in
• May 14, 2019, the Food and Drug Administration approved avelumab of Merck and Pfizer (BAVENCIO, EMD Serono, Inc.) in combination with Inlyta (axitinib) for first-line treatment of patients with advanced RCC (RCC).
• May 2019, NEO-PV-01, an investigational agent developed by Neon Therapeutics, shows promise in early trials for advanced melanoma.
• February 15, 2019, the FDA accepted and granted Priority Review for a new supplemental biologics license application (sBLA) for Merck’s pembrolizumab, an anti­–programmed cell death protein 1 (PD-1) therapy, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced RCC.
• In January 2019, Merck’s KEYTRUDA® (pembrolizumab) received five new approvals in Japan, including adjuvant therapy for Melanoma.
• In Nov 2018, Teva pharmaceuticals had received FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-overexpressing Breast Cancer.
• In January 2018, Biocon and Sandoz entered into a strategic partnership to develop the next generation of biosimilars in cancer and immunology.

 Key Takeaways:

• The global market for the oncology therapy market is primarily driven by the rise in incidences of cancer, which has led to rise in demand for cancer drugs, increased demand for precision medicine.
• Targeted therapy holds a significant market share owing to its high cure rate and increased survival rate, fewer side effects offered by the treatment compared to the conventional therapy and cost-effective nature.

View full report: https://www.datamintelligence.com/research-report/oncology-therapy-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/oncology-therapy-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com